Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer

NCT02292758 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT02292758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02292758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Completed
Start date
December 12, 2014
Completion date
September 27, 2019
Enrollment
36 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, ras wild type, stage iv colorectal cancer ajcc v7, stage iva colorectal cancer ajcc v7, stage ivb colorectal cancer ajcc v7